BMS's $1 Billion Bet on Next-Gen ADC Reaches Key Clinical Milestone
Tubulis
Developer of Drug Conjugates
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
▲August 1-22025 Biopharmaceutical Innovation ExpoScan to register
Note:This article does not constitute any investment opinions or suggestions., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted requires authorization.
Recently, GermanyTubulis GmbH announced a collaboration withThe first project of Bristol-Myers Squibb (BMS) collaboration has entered the clinical development stage, marking an important milestone in the ongoing collaborative development of next-generation antibody-drug conjugate (ADC) candidates for cancer treatment.
The two companies signed a cooperation agreement in April 2023.BMS with$22.75 Million Upfront Payment, acquiring Tubulis' proprietary P5 conjugates and Tubutecan platform, aiming to combine BMS' deep oncology and clinical development expertise with Tubulis' unique ADC design approach to develop versatile and customizable ADC drugs for cancer treatment.The total amount may exceed 1 billion US dollars, plus a tiered royalty on net product sales.
Tubulis CEO and co-founder Dominik Schumacher, Ph.D., stated,Within just one year, we have advanced three tubutecan-based ADC candidates into clinical trials, including our wholly owned programs TUB-030 and TUB-040, and we will continue to demonstrate the versatility and translational potential of our technology in delivering more effective cancer treatments.
After BMS selects the antibody target, Tubulis will provide its linker payload to the company, creating a uniquely matched ADC for each antibody. Bristol-Myers Squibb Company will be solely responsible for the development, manufacturing, and commercialization of the resulting ADC candidates.
December 2024,Gilead and TubulisAlso signed an exclusive option and license agreement to discover and develop ADCs targeting solid tumor antigens. According to the agreement,Tubulis to Receive $20 Million Upfront Payment and Additional $30 Million Option Exercise Fee if Gilead Exercises Its Option.In addition, Tubulis will be eligible to receiveTotaling up to $415 millionDevelopment and commercialization milestone payments, as well as tiered royalties in the mid-single-digit to low-double-digit range on sales of marketed products resulting from the collaboration.
References:
https://tubulis.com/
Copyright Statement: This article is reproduced fromThe Era of Biologics，Media or individuals who do not wish to be reproduced can contact us, and we will delete it immediately.
Rooted in Shanghai and radiating globally, PharmaCircle, as a strategic platform for the biopharmaceutical industry, is on a mission to "enable the borderless flow of intelligence and networks." It has built an empowerment system covering the entire pharmaceutical industry chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connectivity, industry think tanks, and ecosystem communities—it is creating the infrastructure for the flow of pharmaceutical value in China.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we weave a global network of pharmaceutical intelligence, making every precise connection a catalyst for leapfrog growth in enterprises.